Milestone Scientific Inc. (MLSS) — SEC Filings
Milestone Scientific Inc. (MLSS) — 23 SEC filings. Latest: 8-K (Apr 21, 2026). Includes 14 8-K, 5 10-Q, 2 DEF 14A.
View Milestone Scientific Inc. on SEC EDGAR
Overview
Milestone Scientific Inc. (MLSS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: On March 31, 2026, Milestone Scientific Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement's nature or any associated dollar amounts. The company's mailing and business address is 220 South Orange Avenue, Livingston, NJ 07039.
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 5 bearish, 17 neutral, 1 mixed. The dominant filing sentiment for Milestone Scientific Inc. is neutral.
Filing Type Overview
Milestone Scientific Inc. (MLSS) has filed 14 8-K, 2 DEF 14A, 5 10-Q, 2 10-K with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of MLSS's 20 recent filings, 3 were flagged as high-risk, 12 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4,555,886 |
| Net Income | -$3,477,696 |
| EPS | N/A |
| Debt-to-Equity | 1.41 |
| Cash Position | $1,274,314 |
| Operating Margin | N/A |
| Total Assets | $8,050,830 |
| Total Debt | $4,710,558 |
Key Executives
- Benedetta I. Casamento
- Neal Goldman
- Eric Hines
- Dr. Didier Demesmin
- Shanth Thiyagalingam
- Dr. Dawood Sayed
Industry Context
Milestone Scientific Inc. operates in the medical device sector, focusing on innovative technologies for diagnostic and therapeutic applications. The industry is characterized by rapid technological advancements, stringent regulatory oversight from bodies like the FDA, and a competitive landscape with both established players and emerging startups. Success often hinges on securing intellectual property, navigating complex reimbursement pathways, and demonstrating clinical efficacy and safety.
Top Tags
corporate-governance (4) · 10-Q (4) · financials (4) · executive-compensation (3) · governance (3) · Net Loss (2) · director-change (2) · loss (2) · Financials (2) · material-agreement (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Proposed authorized shares of Common Stock | 125,000,000 | Increase from current 100,000,000 shares |
| Current authorized shares of Common Stock | 100,000,000 | To be increased to 125,000,000 |
| Outstanding shares of common stock | 78,628,913 | As of the November 4, 2025 Record Date |
| Number of directors to be elected | 6 | Current board size and nominees |
| Annual Meeting Date and Time | 2025-12-18T09:00:00.000Z | Virtual-only meeting at 9:00 a.m. (ET) |
| Record Date | 2025-11-04T00:00:00.000Z | For determining stockholders entitled to vote |
| Internet voting deadline | 2025-12-17T23:59:00.000Z | 11:59 p.m., Eastern Time |
| Net loss for Q2 2025 | $1,483,110 | Increased from a net income of $223,638 in Q2 2024 |
| Net loss for H1 2025 | $3,477,696 | Worsened from a net loss of $1,216,891 in H1 2024 |
| Cash and cash equivalents as of June 30, 2025 | $1,274,314 | Decreased significantly from $3,258,058 at December 31, 2024 |
| Accumulated deficit since inception | $131.5 million | Indicates a history of significant losses |
| Product sales, net for Q2 2025 | $2,323,466 | Increased from $1,853,764 in Q2 2024 |
| Product sales, net for H1 2025 | $4,555,886 | Increased from $4,102,609 in H1 2024 |
| Net cash used in operating activities for H1 2025 | $2,772,273 | Increased from $434,473 in H1 2024, indicating higher cash burn |
| Convertible notes payable to related parties | $800,000 | New debt incurred during H1 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Milestone Scientific Inc. (MLSS)?
Milestone Scientific Inc. has 23 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MLSS filings?
Across 23 filings, the sentiment breakdown is: 5 bearish, 17 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Milestone Scientific Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Milestone Scientific Inc. (MLSS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Milestone Scientific Inc.?
Key financial highlights from Milestone Scientific Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MLSS?
The investment thesis for MLSS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Milestone Scientific Inc.?
Key executives identified across Milestone Scientific Inc.'s filings include Benedetta I. Casamento, Neal Goldman, Eric Hines, Dr. Didier Demesmin, Shanth Thiyagalingam and 1 others.
What are the main risk factors for Milestone Scientific Inc. stock?
Of MLSS's 20 assessed filings, 3 were flagged high-risk, 12 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Milestone Scientific Inc.?
Forward guidance and predictions for Milestone Scientific Inc. are extracted from SEC filings as they are enriched.